Literature DB >> 26945446

Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas.

Jaudah A Al-Maghrabi1, Nadeem S Butt, Nisrin Anfinan, Khalid Sait, Hesham Sait, Anas Marzouki, Mohamad Nidal Khabaz.   

Abstract

INTRODUCTION: Many studies described napsin A as a specific diagnostic marker that aids in differentiating lung adenocarcinomas from other respiratory tumors. This study describes the expression phenotype of napsin A in endometrial neoplasms, it investigates the relationship between this expression profile and the clinicopathologic parameters, and assess its utilization as an independent predictive marker.
METHODS: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, and 2 malignant mixed mullerian tumors) and 30 tissue samples of noncancerous endometrium (including 16 proliferative endometriums, 10 secretory endometriums and 4 endometrial polyps) were retrieved from the archives of Pathology Department at King Abdulaziz University, Jeddah, Saudi Arabia. For napsin A detection, tissue microarrays and immunostaining were used.
RESULTS: A total number of 12 (15.78%) cases were positive for napsin A immunostaining. Brown granular cytoplasmic expression of napsin A was detected in 9.4% of endometrioid adenocarcinomas, 16.7% of endometrioid adenocarcinomas with squamous differentiation, 22.2% of papillary serous endometrial carcinomas, and 66.7% of clear cell carcinomas. Three (10%) control cases showed similar granular cytoplasmic expression. Positive napsin A immunostaining was more frequent in clear cell carcinoma, and there is a significant association between positive napsin A immunostaining and clear cell carcinoma (P-value=0.007). Significant associations have been found also between napsin A expression and older ages (above 60 y) and higher stage (IVB), the P-values of which were 0.035 and 0.043, respectively, but not with the tumor recurrence or survival rate.
CONCLUSIONS: Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 26945446     DOI: 10.1097/PAI.0000000000000350

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

Review 1.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

2.  Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.

Authors:  Xiyin Wang; Jillian R H Wendel; Robert E Emerson; Russell R Broaddus; Chad J Creighton; Douglas B Rusch; Aaron Buechlein; Francesco J DeMayo; John P Lydon; Shannon M Hawkins
Journal:  Oncogene       Date:  2020-08-25       Impact factor: 9.867

3.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases.

Authors:  Zhiyang Zhang; Penglian Gao; Zhengqi Bao; Linggong Zeng; Junyi Yao; Damin Chai; Tian Li
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

4.  Napsin-A Expression, a Reliable Immunohistochemical Marker for Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.

Authors:  Fatemeh Nili; Mansoureh Tavakoli; Narges Izadi Mood; Hana Saffar; Soheila Sarmadi
Journal:  Iran J Pathol       Date:  2020-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.